You are here: Industry Insights > J&J

News List

J&J ordered to pay $4.68 billion to talc-powder plaintiffs pharmafile
July 17, 2018
A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women who claimed that the multinational’s talc-based products had caused them to develop ovarian cancer.
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial pharmatimes
July 16, 2018
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Trump’s U.K. visit sparks plans for mass protests—and dinner invites for GSK, J&J CEOs fiercepharma
July 06, 2018
But some business leaders say they’re skeptical the gathering will go forward, according to the report.
J&J agrees to sell LifeScan unit for $2.1B biospectrumasia
June 14, 2018
Johnson & Johnson accepted Platinum Equity's $2.1 billion offer for LifeScan, the company's blood glucose monitoring unit known for its OneTouch brand of glucose meters and insulin pumps.
J&J partners with Boston University to tackle lung cancer pharmatimes
June 13, 2018
Johnson & Johnson Innovation has launched a five-year partnership with Boston University to develop new solutions for the prevention, interception and curing of lung cancer.
J&J pays out $37m in damages over claims its talc contains asbestos pharmafile
April 08, 2018
Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out $37 million in damages after losing the first trial in a legal dispute which alleges that its Baby Powder product contains the carcinogenic ingredient asbest
J&J to invest $3.9 M in Singapore R&D biospectrumasia
March 15, 2018
The winning applications sought to pursue novel approaches in the areas of eye health, cancer and liver disease.
J&J Bows Out of Race for Pfizer's $20B Consumer Health Biz biospace
January 29, 2018
Late in 2017, Johnson & Johnson indicated it was interested in selling its consumer health business. Several companies, including Johnson & Johnson, GlaxoSmithKline and Reckitt Benckiser have been interested, according to insiders
J&J struck by €25m fine over fentanyl pain patch pharmafile
December 21, 2017
Johnson & Johnson has been fined by France’s competition authority, Autorité de la Concurrence, after it alleges the company had intentionally stifled generic competition to its painkille
J&J's Darzalex cuts risk of disease progression and death by 50%, new study shows pharmafile
December 14, 2017
Johnson & Johnson data show that Darzalex, when used in combination with bortezomib, melphalan and prednisone, is capable of reducing the risk of disease progression or death from newly diagnosed multiple myeloma patients treated with autologous stem cell

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page